Search

Your search keyword '"Höglund, Martin"' showing total 141 results

Search Constraints

Start Over You searched for: Author "Höglund, Martin" Remove constraint Author: "Höglund, Martin" Database Unpaywall Remove constraint Database: Unpaywall
141 results on '"Höglund, Martin"'

Search Results

3. P506: CLINICAL VALIDATION OF THE NORDIC GUIDELINES FOR GERMLINE TESTING IN MYELOID NEOPLASMS: RESULTS FROM A MULTI-CENTER PROSPECTIVE COHORT STUDY

4. P513: MOLECULAR PATTERN BY AGE AND OVERALL SURVIVAL IN ACUTE MYELOID LEUKEMIA: A POPULATION-BASED STUDY FROM THE SWEDISH AML REGISTRY.

5. S181: THE PHASE III, RANDOMIZED COMMODORE 2 TRIAL: RESULTS FROM A MULTICENTER STUDY OF CROVALIMAB VS ECULIZUMAB IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PATIENTS NAIVE TO COMPLEMENT INHIBITORS

6. Next generation pan-cancer blood proteome profiling using proximity extension assay

8. The impact of Covid-19 in patients with chronic myeloid leukemia—a nationwide population-based study

9. Supplementary Figures 1 through 3 from The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses

11. Supplementary Figures 1 through 3 from The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses

12. Figure S2 from A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia

13. Table S1 from A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia

14. Figure S1 from A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia

15. Table S1 from A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia

16. Proteogenomic analysis of acute myeloid leukemia associates relapsed disease with reprogrammed energy metabolism both in adults and children

17. Noninvasive detection of any-stage cancer using free glycosaminoglycans

18. Plasma protein biomarker profiling reveals major differences between acute leukaemia, lymphoma patients and controls

19. IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia

20. Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications

21. Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial

23. A Study Protocol for Validation and Implementation of Whole-Genome and -Transcriptome Sequencing as a Comprehensive Precision Diagnostic Test in Acute Leukemias

25. A risk score based on real-world data to predict early death in acute promyelocytic leukemia

26. Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow‐up of patients diagnosed 2002–2017 in a complete coverage and nationwide agnostic register study

27. Transcriptomic analysis reveals proinflammatory signatures associated with acute myeloid leukemia progression

31. Successful tyrosine kinase inhibitor discontinuation outside clinical trials — data from the population‐based Swedish chronic myeloid leukaemia registry

33. Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? A population-based study

34. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

35. Genomic characterization of relapsed acute myeloid leukemia reveals novel putative therapeutic targets

38. Clinical and genomic characterization of patients diagnosed with the provisional entity acute myeloid leukemia with BCR‐ABL1, a Swedish population‐based study

39. 853 Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients

40. Vitamin D levels and busulphan kinetics in patients undergoing hematopoietic stem cell transplantation, a multicenter study

44. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia

47. The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting

49. Real‐world data on treatment patterns and outcomes of hypomethylating therapy in patients with newly diagnosed acute myeloid leukaemia aged ≥ 60 years

Catalog

Books, media, physical & digital resources